Evidence map›Paper›PMID 42064801›Full record

ReviewFrontiers in pharmacology2026

Assessing biological activities of polyphenols in the context of 4R - challenges of a ubiquitous compound class with complex modes of action.

Verena Spiegler

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Verena SpieglerInstitute of Pharmaceutical Biology and Phytochemistry, University of Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polyphenols are widespread in plants used for nutritional and medicinal purposes, and have been associated with multiple beneficial effects on health. From a drug development perspective, however, many polyphenols have been disapproved as lead structures and designated as nuisance compounds. Nevertheless, research on health promoting effects of polyphenols has continuously increased over the past decade. Given their ubiquitous presence in plants and their occurrence as mixtures, an application in form of herbal preparations could be more advantageous than the administration of single compounds with numerous, but often weak effects of unclear relevance. Currently, the most powerful technique attempting to capture the entirety of pleiotropic activities of herbal medicines is network pharmacology. However, the major challenges and limitations related to assessing the pharmacological effects of polyphenols, such as unspecific interactions in assays, pharmacokinetic properties and synergisms among extract ingredients largely remain, and can lead to uncertainties regarding the validity of the data input. Especially in light of the 4R principle for animal experimentation, attention to planning meaningful experiments continues to be of high importance when studying bioactivities of polyphenols. This mini review therefore revisits characteristics and challenges associated with pharmacological investigations of polyphenolic natural products to discuss them in the context of 4R.

Indexed as

4Rbioavailabilityin vitro assaypleiotropic effectspolyphenol

Identifiers

PMID42064801
PMCPMC13125092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.